AGIOS PHARMACEUTICALS, INC. Realized Investment Gains (Losses)
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Realized Investment Gains (Losses) of $95.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. realized investment gains (losses) for the quarter ending 2026-06-30 was $67.00K.
- AGIOS PHARMACEUTICALS, INC. realized investment gains (losses) for the quarter ending 2026-03-31 was $28.00K, a 1300.00% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. realized investment gains (losses) for the quarter ending 2025-12-31 was $118.00K.
- AGIOS PHARMACEUTICALS, INC. realized investment gains (losses) for the quarter ending 2025-09-30 was -$2.00K, a 113.33% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. realized investment gains (losses) for fiscal 2025 was $118.00K, a 29.34% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. realized investment gains (losses) for fiscal 2024 was $167.00K, a 496.43% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. realized investment gains (losses) for fiscal 2023 was $28.00K.
| Period end | Realized Investment Gains (Losses) 3 month | Realized Investment Gains (Losses) 6 month | Realized Investment Gains (Losses) 9 month | Realized Investment Gains (Losses) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $95.00K 10-Q · filed 2026-07-30 | $213.00K derived: sum of 3 quarters · filed 2026-07-30 | $211.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $28.00K 10-Q · filed 2026-04-29 | $146.00K derived: sum of 2 quarters · filed 2026-04-29 | $144.00K derived: sum of 3 quarters · filed 2026-04-29 | $144.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $116.00K derived: sum of 2 quarters · filed 2026-02-12 | $116.00K derived: sum of 3 quarters · filed 2026-07-30 | $118.00K 10-K · filed 2026-02-12 |
| 2025-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$2.00K derived: sum of 2 quarters · filed 2026-07-30 | $0.00 10-Q · filed 2025-10-30 | -$1.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.00K 10-Q · filed 2026-07-30 | $1.00K derived: sum of 3 quarters · filed 2026-07-30 | $16.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $2.00K 10-Q · filed 2026-04-29 | $1.00K derived: sum of 2 quarters · filed 2026-04-29 | $16.00K derived: sum of 3 quarters · filed 2026-04-29 | $17.00K derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $14.00K derived: sum of 2 quarters · filed 2026-02-12 | $15.00K derived: sum of 3 quarters · filed 2026-02-12 | $167.00K 10-K · filed 2026-02-12 |
| 2024-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $16.00K derived: sum of 2 quarters · filed 2025-10-30 | $168.00K 10-Q · filed 2025-10-30 | $168.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $153.00K 10-Q · filed 2025-07-31 | $153.00K derived: sum of 3 quarters · filed 2026-02-12 | $181.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $152.00K 10-Q · filed 2025-05-01 | $152.00K derived: sum of 2 quarters · filed 2026-02-12 | $180.00K derived: sum of 3 quarters · filed 2026-02-12 | $180.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $28.00K derived: sum of 2 quarters · filed 2026-02-12 | $28.00K derived: sum of 3 quarters · filed 2026-02-12 | $28.00K 10-K · filed 2026-02-12 |
| 2023-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $28.00K derived: sum of 2 quarters · filed 2024-10-31 | $28.00K 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |